Cancer Stem Cells: A Moving Target

Current Pathobiology Reports

Volumn 1, Issue 2, 2013, Pages 111-118

  Francipane, Maria Giovanna ^a,b   Chandler, Julie M ^a   Lagasse, Eric ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Istituto Mediterraneo per i Trapianti e Terapie (ISMETT) Ad Alta Specializzazione RIMED Foundation   (Italy)

Author keywords

ABC transporters; Cancer; Cancer stem cells; CSCs; DNA repair; Drug resistance; Genomic instability; Pathobiology

Indexed keywords

EID: 84890204540     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-013-0010-2     Document Type: Review

References (89)

1. Ashley N (2012) Regulation of intestinal cancer stem cells. Cancer Lett. doi:10.1016/j.canlet.2012.04.016
2. Nagano O, Okazaki S, Saya H (2013) Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. doi:10.1038/onc.2012.638
3. Kenyon J, Gerson SL (2007) The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res 35:7557–7565
4. Rocha CR, Lerner LK, Okamoto OK et al (2012) The role of DNA repair in the pluripotency and differentiation of human stem cells. Mutat Res 752:25–35
5. ∙ Blanpain C, Mohrin M, Sotiropoulou PA et al (2011) DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8:16–29. In this review, the authors discuss how CSCs may take advantage of the mechanisms of DNA repair used by tissue-specific SCs to mediate resistance to chemo- and radiotherapy
6. Hirschmann-Jax C, Foster AE, Wulf GG et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233
7. Zhou S, Schuetz JD, Bunting KD et al (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034
8. Cohnheim J (1867) Ueber Entzündung und Eiterung. Virchows Arch Path Anat 40:1–79
9. Lapidot T, Sirard C, Vormoor J et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648
10. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
11. Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988
12. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401
13. O’Brien CA, Pollett A, Gallinger S et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115
15. Eppert K, Takenaka K, Lechman ER et al (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086–1093
16. Barker N, van Es JH, Kuipers J et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449:1003–1007
17. Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120
18. Kemper K, Sprick MR, de Bree M et al (2010) The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70:719–729
19. Dalerba P, Dylla SJ, Park IK et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158–10163
20. Odoux C, Fohrer H, Hoppo T et al (2008) A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 68:6932–6941
21. Afify A, Purnell P, Nguyen L (2009) Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 86:95–100
22. Wielenga VJ, Heider KH, Offerhaus GJ et al (1993) Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53:4754–4756
23. Weg-Remers S, Anders M, von Lampe B et al (1998) Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur J Cancer 34:1607–1611
24. Kaufmann M, Heider KH, Sinn HP et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345:615–619
25. Noordzij MA, van Steenbrugge GJ, Schroder FH et al (1999) Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 84:478–483
26. Gao AC, Lou W, Dong JT et al (1997) CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 57:846–849
27. Harada N, Mizoi T, Kinouchi M et al (2001) Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 91:67–75
28. Dallas MR, Liu G, Chen WC et al (2012) Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J 26:2648–2656
29. Rudzki Z, Jothy S (1997) CD44 and the adhesion of neoplastic cells. Mol Pathol 50:57–71
30. Cheng W, Liu T, Wan X et al (2012) MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 279:2047–2059
31. Wang L, Su W, Liu Z et al (2012) CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 33:5107–5114
32. Vermeulen L, De Sousa EMF, van der Heijden M et al (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468–476
33. Merchant AA, Matsui W (2010) Targeting Hedgehog: a cancer stem cell pathway. Clin Cancer Res 16:3130–3140
34. Pannuti A, Foreman K, Rizzo P et al (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16:3141–3152
35. Sell S (1993) Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect 101(Suppl 5):15–26
36. Jaiswal S, Traver D, Miyamoto T et al (2003) Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 100:10002–10007
37. Guibal FC, Alberich-Jorda M, Hirai H et al (2009) Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 114:5415–5425
38. ∙∙ Friedmann-Morvinski D, Bushong EA, Ke E et al (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338:1080–1084. This is the first clear evidence of dedifferentiation of mature cells towards a more progenitor (SC) state
39. Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
40. Dittmar T, Nagler C, Schwitalla S et al (2009) Recurrence cancer stem cells: made by cell fusion? Med Hypotheses 73:542–547
41. Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296
42. Johnson RA, Wright KD, Poppleton H et al (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632–636
43. Gibson P, Tong Y, Robinson G et al (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095–1099
44. ∙∙ Magee JA, Ikenoue T, Nakada D et al (2012) Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11:415–428. This is the first clear evidence of the involvement of temporal changes in the regulation of HSC function and leukemogenesis
45. Downing JR, Shannon KM (2002) Acute leukemia: a pediatric perspective. Cancer Cell 2:437–445
46. Fuchs E (2009) The tortoise and the hair: slow-cycling cells in the stem cell race. Cell 137:811–819
47. Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598
48. Wu X, Northcott PA, Dubuc A et al (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482:529–533
49. Barker N, Ridgway RA, van Es JH et al (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457:608–611
50. Jaiswal AS, Narayan S (2011) Assembly of the base excision repair complex on abasic DNA and role of adenomatous polyposis coli on its functional activity. Biochemistry 50:1901–1909
51. Tudek B, Speina E (2012) Oxidatively damaged DNA and its repair in colon carcinogenesis. Mutat Res 736:82–92
52. Karimi-Busheri F, Rasouli-Nia A, Mackey JR et al (2010) Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 12:R31
53. Gallmeier E, Hermann PC, Mueller MT et al (2011) Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. Stem Cells 29:418–429
54. Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760
55. Chakraborty S, Stark JM, Sun CL et al (2012) Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood 119:6187–6197
56. Salmina K, Jankevics E, Huna A et al (2010) Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 316:2099–2112
57. ∙ Moitra K, Lou H, Dean M (2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491–502. The authors well describe how ABC efflux pumps can afford protection to CSCs, shielding them from the adverse effects of chemotherapeutic insult
58. Schinkel AH, Smit JJ, van Tellingen O et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502
59. Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1:93–105
60. Patel BB, Gupta D, Elliott AA et al (2010) Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 30:319–325
61. Oh PS, Patel VB, Sanders MA et al (2011) Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. Am J Physiol Gastrointest Liver Physiol 301:G347–G355
62. Fang DD, Kim YJ, Lee CN et al (2010) Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer 102:1265–1275
63. Bleau AM, Huse JT, Holland EC (2009) The ABCG2 resistance network of glioblastoma. Cell Cycle 8:2936–2944
64. Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281–16286
65. Jin Y, Bin ZQ, Qiang H et al (2009) ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 135:1369–1376
66. Wang YH, Li F, Luo B et al (2009) A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56:371–378
67. Lainey E, Sebert M, Thepot S et al (2012) Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 11:4079–4092
68. Niu Q, Wang W, Li Y et al (2012) Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation. PLoS One 7:e41035
69. Yuan JH, Cheng JQ, Jiang LY et al (2008) Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomed Environ Sci 21:290–295
70. Shi GM, Xu Y, Fan J et al (2008) Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134:1155–1163
71. Vander Borght S, van Pelt J, van Malenstein H et al (2008) Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: a study in patients and in vitro. Hepatol Res 38:1112–1121
72. Bitarte N, Bandres E, Boni V et al (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29:1661–1671
73. Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
74. Woodward WA, Chen MS, Behbod F et al (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104:618–623
75. Keysar SB, Jimeno A (2010) More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 9:2450–2457
76. Cobaleda C, Cruz JJ, Gonzalez-Sarmiento R et al (2008) The emerging picture of human breast cancer as a stem cell-based disease. Stem Cell Rev 4:67–79
77. Sato T, Vries RG, Snippert HJ et al (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:262–265
78. ∙ Schepers AG, Snippert HJ, Stange DE et al (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337:730–735. The authors demonstrate that the crypt stem cell marker Lgr5 also marks a subpopulation of adenoma cells that fuel the growth of established intestinal adenomas
79. Wu XS, Xi HQ, Chen L (2012) Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol 10:244
80. Walker F, Zhang HH, Odorizzi A et al (2011) LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One 6:e22733
81. Yang Q, Bermingham NA, Finegold MJ et al (2001) Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294:2155–2158
82. Jensen J, Pedersen EE, Galante P et al (2000) Control of endodermal endocrine development by Hes-1. Nat Genet 24:36–44
83. Sikandar SS, Pate KT, Anderson S et al (2010) NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 70:1469–1478
84. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233
85. Ghaleb AM, Aggarwal G, Bialkowska AB et al (2008) Notch inhibits expression of the Kruppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res 6:1920–1927
86. Milano J, McKay J, Dagenais C et al (2004) Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82:341–358
87. van Es JH, van Gijn ME, Riccio O et al (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435:959–963
88. Kondratyev M, Kreso A, Hallett RM et al (2012) Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 31:93–103
89. Guilmeau S (2012) Notch signaling and intestinal cancer. Adv Exp Med Biol 727:272–288